DAB2IP loss confers the resistance of prostate cancer to androgen deprivation therapy through activating STAT3 and inhibiting apoptosis

por Zhou, J, Ning, Z, Wang, B, Yun, E-J, Zhang, T, Pong, R-C, Fazli, L, Gleave, M, Zeng, J, Fan, J, Wang, X, Li, L, Hsieh, J-T, He, D, Wu, K
Publicado 2015